Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)

NCT03732495 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT03732495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03732495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Unknown status
Start date
July 26, 2019
Completion date
January 15, 2023
Enrollment
35 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer metastatic